Sickle Cell Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Sickle Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 157 trials

Recruiting
Phase 3

The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease

Sickle Cell Disease
Sanofi192 enrolled53 locationsNCT06975865
Recruiting
Not Applicable

Sickle Cell, Pain and Mediterranean Diet

Sickle Cell DiseaseMediterranean DietSickle Cell+1 more
University of Illinois at Chicago30 enrolled1 locationNCT06886477
Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

Sickle Cell DiseaseMalariaAlpha and Beta Thalassemia+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT03937817
Recruiting
Phase 2

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease
Agios Pharmaceuticals, Inc.56 enrolled32 locationsNCT06924970
Recruiting
Phase 2

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Sickle Cell Disease Vaso-occlusive Crisis
CSL Behring70 enrolled15 locationsNCT06699849
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Sickle Cell Disease
Novartis Pharmaceuticals315 enrolled30 locationsNCT06439082
Recruiting
Phase 1

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

Sickle Cell Disease
Fulcrum Therapeutics24 enrolled6 locationsNCT07431398
Recruiting
Phase 1

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease
Disc Medicine, Inc24 enrolled3 locationsNCT07187973
Recruiting

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Sickle Cell Disease
St. Jude Children's Research Hospital352 enrolled1 locationNCT04416178
Recruiting

Functional Ovarian Reserve in Sickle Cell Disease

Sickle Cell Disease
St. Jude Children's Research Hospital440 enrolled1 locationNCT07392216
Recruiting
Phase 3

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Sickle Cell Disease
Novo Nordisk A/S408 enrolled172 locationsNCT06612268
Recruiting
Phase 3

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Sickle Cell DiseaseThalassemia
Novo Nordisk A/S480 enrolled103 locationsNCT06609226
Recruiting
Phase 2

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

Sickle Cell Disease
Forma Therapeutics, Inc.50 enrolled18 locationsNCT06198712
Recruiting
Not Applicable

Exercise in Child Health

Cystic FibrosisSickle Cell Disease
University of California, Irvine240 enrolled1 locationNCT05359991
Recruiting
Not Applicable

Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease

Sickle Cell Disease
Ohio State University287 enrolled4 locationsNCT06919224
Recruiting
Phase 2Phase 3

A Phase 2/3 Study in Adult and Adolescent Participants With SCD

Sickle Cell Disease
Pfizer389 enrolled49 locationsNCT05431088
Recruiting
Phase 3

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Beta-ThalassemiaSickle Cell DiseaseHematologic Diseases+4 more
Vertex Pharmaceuticals Incorporated26 enrolled6 locationsNCT05477563
Recruiting
Not Applicable

Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in Ghana

Sickle Cell Disease and Pregnancy
University of Ghana Medical School198 enrolled1 locationNCT07488091
Recruiting
Phase 2

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

Sickle Cell DiseaseDiffuse Myocardial Fibrosis
Children's Hospital Medical Center, Cincinnati24 enrolled1 locationNCT05012631
Recruiting
Phase 1Phase 2

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Healthy VolunteersAnemia, Sickle Cell
Bristol-Myers Squibb184 enrolled19 locationsNCT06481306